Literature DB >> 24094380

Vancomycin-resistant enterococci.

Ethan Rubinstein1, Yoav Keynan.   

Abstract

Vancomycin-resistant enterococci (VRE) consist mainly of Enterococcus faecalis and E faecium, the latter mostly hospital-acquired. In addition, E gallinarum and E casseliflavus are intrinsically vancomycin-resistant and are community-acquired. VRE have become common in many hospitals throughout the world and, once established, are very difficult to eradicate. VRE are difficult to treat; therefore, infection control measures in hospitals are of prime importance in preventing the establishment of these pathogens. Most severe VRE infections will need combination therapy because many of the effective antimicrobial agents, when used alone, have only a bacteriostatic effect.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Critical care; Enterococcus; Gram-positive cocci; Infection; Resistant pathogen; Vancomycin

Mesh:

Substances:

Year:  2013        PMID: 24094380     DOI: 10.1016/j.ccc.2013.06.006

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  21 in total

1.  Safety assessment of commensal enterococci from dogs.

Authors:  Ivana Kubašová; Viola Strompfová; Andrea Lauková
Journal:  Folia Microbiol (Praha)       Date:  2017-03-18       Impact factor: 2.099

2.  Soft Tissue and Wound Infections Due to Enterococcus spp. Among Hospitalized Trauma Patients in a Developing Country.

Authors:  Nonika Rajkumari; Purva Mathur; Mahesh Chandra Misra
Journal:  J Glob Infect Dis       Date:  2014-10

3.  In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

Authors:  Alexander J Lepak; Karen Marchillo; William A Craig; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

4.  Longitudinal Evaluation of Gut Bacteriomes and Viromes after Fecal Microbiota Transplantation for Eradication of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Qin Liu; Tao Zuo; Wenqi Lu; Yun Kit Yeoh; Qi Su; Zhilu Xu; Whitney Tang; Keli Yang; Fen Zhang; Louis H S Lau; Rashid N S Lui; Miu Ling Chin; Rity Wong; Chun Pan Cheung; Wenyi Zhu; Paul K S Chan; Francis K L Chan; Grace C Lui; Siew C Ng
Journal:  mSystems       Date:  2022-06-01       Impact factor: 7.324

5.  Investigation of the antibacterial effects of silver-modified TiO2 and ZnO plasmonic photocatalysts embedded in polymer thin films.

Authors:  Szabolcs Péter Tallósy; László Janovák; Judit Ménesi; Elisabeth Nagy; Ádám Juhász; László Balázs; István Deme; Norbert Buzás; Imre Dékány
Journal:  Environ Sci Pollut Res Int       Date:  2014-02-05       Impact factor: 4.223

6.  Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

7.  Vancomycin-Resistant Enterococci and Bacterial Community Structure following a Sewage Spill into an Aquatic Environment.

Authors:  Suzanne Young; Bina Nayak; Shan Sun; Brian D Badgley; Jason R Rohr; Valerie J Harwood
Journal:  Appl Environ Microbiol       Date:  2016-08-30       Impact factor: 4.792

8.  Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents.

Authors:  Varsha Gupta; Nidhi Singla; Preeti Behl; Tripti Sahoo; Jagdish Chander
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

9.  Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.

Authors:  W R Heizmann; P-A Löschmann; C Eckmann; C von Eiff; K-F Bodmann; C Petrik
Journal:  Infection       Date:  2014-11-04       Impact factor: 3.553

10.  Vancomycin gene selection in the microbiome of urban Rattus norvegicus from hospital environment.

Authors:  Thomas Arn Hansen; Tejal Joshi; Anders Rhod Larsen; Paal Skytt Andersen; Klaus Harms; Sarah Mollerup; Eske Willerslev; Kurt Fuursted; Lars Peter Nielsen; Anders Johannes Hansen
Journal:  Evol Med Public Health       Date:  2016-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.